The efficacy of tocilizumab, a recombinant monoclonal antibody against IL-6, was tested in severe COVID-19 patients, but with discordant results, either a significant reduction in ventilation dependency [37] or without efficacy [38]. This evidence concerns the gene IL6 and COVID-19.